SS-31 (Elamipretide) Research 2026: FDA Approval Review
22 June 2026 · PepC.Labs
For research use only
This article is research education for laboratory and research-use audiences. Products mentioned are sold strictly for in-vitro research and not for human or veterinary consumption.
In September 2025, the United States Food and Drug Administration granted accelerated approval to elamipretide, marketed as FORZINITY, for the treatment of Barth syndrome. The decision quietly reshaped the mitochondrial peptide research landscape: SS-31, as the molecule is known in the academic literature, became the first mitochondria-targeted peptide therapeutic to clear FDA review and the first approved therapy of any kind for Barth syndrome (Stealth BioTherapeutics, 2025).
For researchers working on mitochondrial dysfunction, the regulatory milestone matters less for the disease label than for what it validates at the bench. Elamipretide is a four-amino-acid peptide whose mechanism of action centres on a single phospholipid: cardiolipin. Two decades of preclinical and translational work have positioned it as one of the most extensively characterised mitochondria-targeted compounds in the literature, with more than 150 peer-reviewed publications spanning ageing biology, ischaemia-reperfusion injury, primary mitochondrial myopathy, and heart failure (Gambardella et al., 2025, International Journal of Molecular Sciences).
This article reviews the current state of SS-31 (elamipretide) research as of 2026, with a focus on the cardiolipin-binding mechanism, the clinical evidence that supported the FDA decision, and the ongoing investigation into mitochondrial-targeted peptides as research tools in ageing biology.
SS-31 Cardiolipin Binding: The Mechanism Behind Mitochondrial Targeting
The defining feature of SS-31 is its molecular targeting strategy. Elamipretide is a synthetic tetrapeptide (D-Arg-2'6'-dimethyltyrosine-Lys-Phe-NH2) carrying two positively charged residues. This cationic character drives selective accumulation in the inner mitochondrial membrane, which is uniquely enriched in cardiolipin, a tetra-acyl phospholipid with a net negative charge (Birk et al., 2014, Journal of the American Society of Nephrology).
Once bound to cardiolipin, SS-31 exerts a stabilising effect on the inner membrane architecture. Cardiolipin is a structural cofactor for multiple electron transport chain complexes, and its peroxidation under oxidative stress disrupts cristae morphology, impairs supercomplex assembly, and reduces ATP synthesis. By selectively associating with cardiolipin, SS-31 reduces lipid peroxidation, preserves cristae curvature, and supports electron transport chain efficiency without requiring a defined receptor.
A 2020 study mapping the mitochondrial protein interaction landscape of SS-31 confirmed that the peptide engages with components of the electron transport chain and mitochondrial protein synthesis machinery, providing a structural basis for its broad effects on bioenergetics (Chavez et al., 2020, PNAS). More recent work has shown that elamipretide also enhances ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator, suggesting the cardiolipin interaction extends to functional regulation of substrate transport across the inner membrane (PubMed: 37462785).
Clinical Evidence: The TAZPOWER Trial and Barth Syndrome Approval
The FDA accelerated approval of elamipretide rested primarily on data from the TAZPOWER trial, a randomised, double-blind, placebo-controlled crossover study in patients with Barth syndrome, an ultra-rare X-linked disorder caused by mutations in the TAZ gene that disrupt cardiolipin remodelling. The trial enrolled adolescent and adult male patients and was followed by an open-label extension that generated the longer-term efficacy signals supporting the regulatory decision (Reid Thompson et al., 2021, Genetics in Medicine).
Across the open-label extension, eight patients showed measurable improvements in six-minute walk distance, with an average gain of approximately 96 metres relative to baseline. Cardiac stroke volume improved, and patient-reported fatigue scores declined. Critically, mature cardiolipin species levels rose during treatment, providing a direct biomarker link between the proposed mechanism and the observed functional improvements.
Parallel research programmes have evaluated elamipretide in primary mitochondrial myopathy through the MMPOWER series of trials. An early dose-escalation study established the pharmacokinetic and safety profile in adults with primary mitochondrial myopathy and identified preliminary signals on six-minute walk distance (Karaa et al., 2018, Neurology). Subsequent phase 3 evaluation in this population produced more equivocal results, illustrating a recurring theme in mitochondrial therapeutics: heterogeneous patient populations and outcome measures complicate interpretation, even when mechanism is well established.
SS-31 in Ageing and Mitochondrial Dysfunction Research
Outside the rare disease setting, the SS-31 evidence base in ageing biology is substantial and continues to expand. The peptide has been studied in models of skeletal muscle decline, cardiac ageing, neurodegeneration, and renal injury, with a consistent pattern of restored mitochondrial bioenergetics following short-term administration.
In aged mice, an eight-week course of SS-31 reversed age-related declines in maximum mitochondrial ATP production and improved coupling of oxidative phosphorylation in skeletal muscle. Treated animals showed greater treadmill endurance and produced gastrocnemius muscles with significantly greater mass and fatigue resistance compared with age-matched controls (Siegel et al., 2013, Aging Cell). A separate body of work in aged murine hearts demonstrated that late-life elamipretide administration restored cardiac function, with improvements in diastolic function and reductions in markers of mitochondrial dysfunction (Chiao et al., 2020, eLife).
More recent investigations have extended these findings into the cerebrovasculature. A 2025 preclinical study evaluated SS-31 in an aged, hypertensive mouse model and identified a protective effect against cerebral microhaemorrhages, with the authors developing a high-throughput imaging pipeline to support future therapeutic screening of cerebromicrovascular protective agents (PubMed: 40169521). These findings position cardiolipin-targeted therapeutics as a candidate strategy in geroscience research, alongside other mitochondrial-derived peptides such as MOTS-c.
For laboratories building research programmes around mitochondrial bioenergetics and ageing, related research-grade peptides such as MOTS-c and antioxidants including Glutathione provide complementary investigative tools.
What the FDA Decision Means for Mitochondrial Peptide Research
The FORZINITY approval is narrowly scoped: it covers adult and paediatric patients with Barth syndrome weighing at least 30 kilograms, and it was granted under the FDA's accelerated approval pathway, which means continued availability is contingent on confirmatory post-marketing data. None of this changes the broader research significance of the decision.
For the first time, regulators have endorsed the cardiolipin-binding mechanism as a clinically valid intervention point for mitochondrial dysfunction. That endorsement provides a reference framework for adjacent research programmes, including the development of next-generation mitochondria-targeted peptides, screening assays based on cardiolipin biology, and translational work in conditions where mitochondrial dysfunction is implicated but no approved therapy exists.
The decision also reframes how mitochondrial-derived peptides as a class are perceived. The discovery of mitochondrial-encoded signalling peptides such as MOTS-c, combined with synthetic mitochondria-targeted constructs such as SS-31, reflects a growing recognition of the mitochondrion as both a source of bioactive molecules and a tractable therapeutic target. Reviews published in 2025 have documented this convergence and forecast continued expansion of the field over the remainder of the decade (Gambardella et al., 2025, International Journal of Molecular Sciences).
For Australian research laboratories tracking developments in this space, research-grade MOTS-c and other cellular bioenergetics peptides are available with certificates of analysis confirming purity specifications.
Summary and Outlook
SS-31, or elamipretide, has progressed from a synthetic tetrapeptide first characterised in the early 2000s to the first FDA-approved mitochondria-targeted peptide therapeutic. Its mechanism of action centres on selective binding to cardiolipin in the inner mitochondrial membrane, where it stabilises membrane architecture, reduces lipid peroxidation, and supports electron transport chain efficiency. The TAZPOWER trial in Barth syndrome provided the pivotal clinical data, while a substantial preclinical literature continues to investigate the peptide in models of ageing, cardiac dysfunction, primary mitochondrial myopathy, and cerebrovascular injury.
Three observations are likely to shape SS-31 research over the next twelve to eighteen months. First, the regulatory precedent established in 2025 is expected to accelerate translational work on cardiolipin-targeted molecules in adjacent indications. Second, the mechanistic overlap between synthetic mitochondria-targeted peptides and endogenous mitochondrial-derived peptides such as MOTS-c is likely to generate combination and comparison studies. Third, the broader peptide research community will continue to monitor confirmatory trials required to convert the accelerated approval into a full approval.
For researchers building investigations around mitochondrial peptides, SS-31 now offers a clinically validated reference compound, and the surrounding ecosystem of research-grade peptides provides the tools for protocol development at the bench.
---
The information in this article is for educational and research purposes only. Products mentioned are intended for laboratory and research use only and are not intended for human consumption. Always consult relevant regulations in your jurisdiction.
References
1. Stealth BioTherapeutics. (2025). FDA Accelerated Approval of FORZINITY (elamipretide HCl) for Barth Syndrome. Press release. stealthbt.com
2. Gambardella, J., et al. (2025). Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International Journal of Molecular Sciences, 26(3), 944. DOI: 10.3390/ijms26030944
3. Reid Thompson, W., et al. (2021). A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genetics in Medicine. PMC7935714
4. Chavez, J.D., et al. (2020). Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences, 117(26), 15363-15373. DOI: 10.1073/pnas.2002250117
5. Karaa, A., et al. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology, 90(14), e1212-e1221. DOI: 10.1212/WNL.0000000000005255
6. Siegel, M.P., et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763-771. PMC6588449
7. Chiao, Y.A., et al. (2020). Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife, 9, e55513. DOI: 10.7554/eLife.55513
8. Birk, A.V., et al. (2014). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250-1261. DOI: 10.1681/ASN.2013020132